{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:54:03Z","timestamp":1790830443721,"version":"4.1.0"},"reference-count":83,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,2,19]],"date-time":"2008-02-19T00:00:00Z","timestamp":1203379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recognition that smallpox is a potential threat agent of bioterrorism has engendered renewed interest in the development of improved vaccines against this pathogen. The purpose of this paper is to review current data regarding novel approaches to smallpox vaccines in comparison with traditional vaccine strategies. The method used is a literature search using overlapping search terms and citations from the relevant, published literature. Substantial animal and limited human data suggest that selected second and third generation smallpox vaccines, specifically tissue\u2010cultured vaccinia virus and replication\u2010competent, highly attenuated vaccinia virus possess immunogenicity and surrogate efficacy profiles similar to those of first generation New York City Board of Health and Lister vaccines. Replication\u2010defective, attenuated vaccinia appears to be less immunogenic in both animals and humans but may have utility as a priming agent in those with contraindications to live vaccinia. There is a clear risk of myopericarditis with first and second generation products, but the relative risk of this complication among various vaccine approaches cannot as yet be determined. The incidence of other serious, albeit uncommon, adverse events of smallpox vaccines cannot be determined for newer vaccine approaches because these agents have not yet been deployed on a scale large enough to discern rare events. Since 2001, progress towards improved smallpox vaccines has been accelerated, spurred on by the threat of bioterrorism. Among newer vaccine candidates, replication\u2010competent, highly attenuated vaccinia and tissue culture\u2010derived live vaccinia appear to offer the greatest potential for efficacy, although it is unclear whether these products offer a safer alternative to existing first generation vaccines. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/rmv.571","type":"journal-article","created":{"date-parts":[[2008,2,19]],"date-time":"2008-02-19T11:16:43Z","timestamp":1203419803000},"page":"217-231","source":"Crossref","is-referenced-by-count":57,"title":["New generation smallpox vaccines: a review of preclinical and clinical data"],"prefix":"10.1002","volume":"18","author":[{"given":"Andrew W.","family":"Artenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2,19]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Encyclopedia of Public Health","author":"Moloo H","year":"2008"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.22.2127"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.2.277"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1009.040310"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780373"},{"key":"e_1_2_1_7_2","volume-title":"Smallpox and its eradication","author":"Fenner F","year":"1988"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020025"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703123161106"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/340517"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020534"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013431"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/511828"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3295"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.10.1205"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.07.082"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/432765"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.079"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(05)70234-8","article-title":"Safety and immunogenicity of new cell\u2010cultured smallpox vaccine compared with calf\u2010lymph derived vaccine: a blind, single\u2010centre, randomized controlled trial","volume":"365","author":"Greenberg RN","year":"2005","journal-title":"Lancet"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/505506"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000229196.41862.c2"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.037"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00392.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1107.050277"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm916"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2004.09.002"},{"key":"e_1_2_1_27_2","unstructured":"Acambis Inc.Investigator's Brochure for ACAM2000 smallpox vaccine. Cambridge MA August2002."},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.046"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.087"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.03.029"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406671102"},{"key":"e_1_2_1_32_2","unstructured":"YokoteH ShinmuraY SatouA et al.Safety and efficacy study of attenuated smallpox vaccine LC16m8 in animals. In2006 ASM Biodefense Research Meeting 15\u201318 February 2006 Washington DC. American Society for Microbiology: Washington DC 2006; p.45 Abstract nr 86 (E)."},{"key":"e_1_2_1_33_2","unstructured":"KennerJR GurwithM LuckA et al.Safety and immunogenicity of attenuated smallpox vaccine LC16m8: results from a phase 2 study. In2006 ASM Biodefense Research Meeting 15\u201318 February 2006 Washington DC. American Society for Microbiology: Washington DC 2006; p.68 Abstract nr 206 (E)."},{"key":"e_1_2_1_34_2","unstructured":"FujiiT KannataniY MatsumuraT et al.Clinical evaluation of attenuated smallpox vaccine LC16m8 in Japan. In2006 ASM Biodefense Research Meeting 15\u201318 February 2006 Washington DC. American Society for Microbiology: Washington DC 2006; p.65 Abstract nr 196 (E)."},{"key":"e_1_2_1_35_2","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)","volume":"167","author":"Mayr A","year":"1978","journal-title":"Zentralbl Bakteriol [B]"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/421266"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00075-5"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401165101"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.06.002"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02331"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7845-7851.2005"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.22.12471-12479.2004"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.02.012"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.022"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.10.047"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02108-05"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/378518"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/427265"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.15.7713-7723.2002"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.06.043"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.18.11724-11733.2005"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.19.10230-10237.2004"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4433-4443.2004"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.02.034"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.4.2552"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196911272812201"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/122.4.303"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1086\/375825"},{"key":"e_1_2_1_59_2","first-page":"1341","article-title":"Frequency of adverse events after vaccination with different vaccinia strains","volume":"3","author":"Kretzschmar M","year":"2006","journal-title":"PLoS Med"},{"issue":"01","key":"e_1_2_1_60_2","first-page":"1","article-title":"Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions","volume":"55","author":"Center for Disease Control and Prevention","year":"2006","journal-title":"MMWR"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.7.925"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.15.1901"},{"key":"e_1_2_1_63_2","first-page":"84","article-title":"Expected adverse events in a mass smallpox vaccination campaign","volume":"5","author":"Kemper AR","year":"2002","journal-title":"Eff Clin Pract"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-6-200303180-00014"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.10.052"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1086\/428731"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3278"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.21.2744"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.017"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1086\/420938"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.21.2734"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.012"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1349"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1983.tb03692.x"},{"key":"e_1_2_1_75_2","first-page":"1099","article-title":"Cardiac complications after vaccination for smallpox","volume":"2","author":"MacAdam D","year":"1962","journal-title":"Br Heart J"},{"key":"e_1_2_1_76_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.0954-6820.1966.tb05079.x","article-title":"ECG\u2010changes without subjective symptoms after smallpox vaccination of military personnel","volume":"464","author":"Ahlborg B","year":"1966","journal-title":"Acta Med Scand Suppl"},{"key":"e_1_2_1_77_2","first-page":"280","article-title":"Myocardial complications of immunizations","volume":"10","author":"Helle EP","year":"1978","journal-title":"Ann Clin Res"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1005.030507"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3283"},{"key":"e_1_2_1_80_2","unstructured":"The U.S. military programme website:www.smallpox.army.mil\/event\/SPSafetySum.asp accessed on 5 January 2008."},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh269"},{"key":"e_1_2_1_82_2","unstructured":"von SonnenburgF PeronaP SchunkM et al.First clinical experience with a third generation smallpox vaccine in subjects with atopic dermatitis. In2006 ASM Biodefense Research Meeting 15\u201318 February 2006 Washington DC. American Society for Microbiology: Washington DC 2006; p.43 Abstract nr 79 (E)."},{"key":"e_1_2_1_83_2","doi-asserted-by":"publisher","DOI":"10.1086\/515331"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00191-2"}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frmv.571","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T23:50:47Z","timestamp":1700005847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,19]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1002\/rmv.571"],"URL":"https:\/\/doi.org\/10.1002\/rmv.571","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"value":"1052-9276","type":"print"},{"value":"1099-1654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,19]]}}}